Insmed, Inc. $INSM Stock: William Blair Investment Management LLC Cuts Stake

William Blair Investment Management LLC trimmed its position in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 1.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 619,049 shares of the biopharmaceutical company’s stock after selling 10,782 shares during the period. William Blair Investment Management LLC owned 0.28% of Insmed worth $70,658,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Russell Investments Group Ltd. increased its stake in shares of Insmed by 101.7% in the third quarter. Russell Investments Group Ltd. now owns 282,873 shares of the biopharmaceutical company’s stock valued at $32,446,000 after purchasing an additional 142,654 shares during the period. Eurizon Capital SGR S.p.A. raised its holdings in shares of Insmed by 35.6% during the third quarter. Eurizon Capital SGR S.p.A. now owns 27,457 shares of the biopharmaceutical company’s stock valued at $3,138,000 after buying an additional 7,210 shares during the last quarter. Bingham Private Wealth LLC boosted its position in shares of Insmed by 15.9% during the third quarter. Bingham Private Wealth LLC now owns 2,287 shares of the biopharmaceutical company’s stock worth $261,000 after buying an additional 314 shares during the period. Maryland State Retirement & Pension System boosted its position in shares of Insmed by 11.2% during the third quarter. Maryland State Retirement & Pension System now owns 12,642 shares of the biopharmaceutical company’s stock worth $1,443,000 after buying an additional 1,273 shares during the period. Finally, Ritholtz Wealth Management acquired a new position in shares of Insmed during the third quarter worth approximately $299,000.

Insmed Price Performance

Shares of Insmed stock traded up $3.09 on Friday, hitting $121.16. The company had a trading volume of 1,543,590 shares, compared to its average volume of 3,815,081. Insmed, Inc. has a 52 week low of $90.39 and a 52 week high of $212.75. The company has a debt-to-equity ratio of 0.77, a current ratio of 2.86 and a quick ratio of 2.59. The company has a market cap of $26.58 billion, a PE ratio of -42.96 and a beta of 0.83. The business has a 50-day simple moving average of $110.82 and a 200-day simple moving average of $123.37.

Insmed (NASDAQ:INSM – Get Free Report) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The firm had revenue of $524.43 million for the quarter, compared to the consensus estimate of $500.36 million. Insmed had a negative return on equity of 96.38% and a negative net margin of 39.85%. Insmed’s revenue for the quarter was up 268.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.75) EPS. Research analysts expect that Insmed, Inc. will post -1.86 EPS for the current fiscal year.

Insider Activity at Insmed

In other news, Director David Brennan sold 25,000 shares of the business’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total value of $3,100,000.00. Following the sale, the director owned 39,238 shares of the company’s stock, valued at approximately $4,865,512. The trade was a 38.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.10% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on INSM. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a research report on Thursday, October 15th. HC Wainwright assumed coverage on Insmed in a research note on Wednesday, November 4th. They set a “buy” rating and a $220.00 target price on the stock. Bank of America reiterated a “buy” rating and set a $207.00 price target on shares of Insmed in a research report on Monday, October 12th. The Goldman Sachs Group assumed coverage on Insmed in a research note on Thursday, September 24th. They issued a “buy” rating and a $188.00 price target for the company. Finally, Evercore reissued an “outperform” rating and set a $170.00 price target on shares of Insmed in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $196.52.

Get Our Latest Report on INSM

About Insmed

(Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.

Featured Stories

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM – Free Report).

Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.